Pfizer pulls sickle cell drug from market

Doctors are struggling to figure out how to advise patients after Pfizer pulled a sickle cell drug from the market this week. The company recalled Oxbryta and ended clinical trials over safety concerns, but sickle cell advocates are warning that stopping the drug abruptly could be dangerous.

Eric Boodman, a general assignment reporter at STAT, joins us to discuss.

This article was originally published on WBUR.org.